In the rapidly evolving landscape of microbiome science, Lactobacillus Rhamnosus GG (LGG) stands as the world's most researched and clinically documented probiotic strain. Discovered in 1985 by Professors Sherwood Gorbach and Barry Goldin, LGG has revolutionized our understanding of intestinal health and immune system modulation. As a premier supplier, Jiangxi Serum Pharma Industries Co., Ltd. provides industry-leading LGG strains characterized by exceptional stability, high viable cell counts, and proven clinical efficacy.
LGG is a Gram-positive, anaerobic, non-spore-forming bacterium. What sets it apart is its unique pili (hair-like structures) that contain the mucus-binding protein SpaC. This evolutionary adaptation allows LGG to adhere robustly to the human intestinal mucosa, facilitating longer colonization times compared to other strains. This prolonged residence time is crucial for competitive exclusion of pathogens and the induction of beneficial immune responses.
Chinese facilities utilize state-of-the-art 50-ton fermenters with automated pH and nutrient controls, ensuring high-density cultivation and unmatched strain purity.
Our specialized cryoprotectant technology protects LGG cells during the lyophilization process, maintaining cell membrane integrity for superior shelf-life stability.
Through vertically integrated supply chains and localized raw material sourcing, we provide premium LGG at a competitive price point without compromising GMP standards.
Continuous genomic sequencing ensures zero drift in the strain's DNA, guaranteeing that every batch delivered matches the original clinical profile.
Emerging research focuses on psychobiotics. LGG is being studied for its role in reducing anxiety and improving cognitive focus via the vagus nerve signaling.
AI-driven microbiome analysis is leading to customized probiotic blends where LGG serves as the foundational "core" strain for digestive resilience.
The transition from live bacteria to heat-inactivated LGG (postbiotics) for stable applications in shelf-stable snacks and beverages is a major market shift.
LGG is the primary choice for preventing atopic dermatitis and antibiotic-associated diarrhea (AAD) in infants, driving huge demand in the pediatric sector.
Stable LGG powders are now integrated into water-soluble sachets and "cap-release" beverage bottles for on-the-go immune support.
Oral intake of LGG has shown systemic benefits for skin barrier function, leading to its inclusion in premium beauty-from-within supplements.
As a natural alternative to antibiotics, LGG is being applied in high-value livestock farming to improve growth rates and reduce enteric infections.
Jiangxi Serum Pharma Industries Co., Ltd. is a professional supplier of pharmaceutical and nutritional products in China. For nearly 10 years, we have been dedicated to exporting biological products, vaccines, Western medicines, raw materials, intermediates, medical consumables, food additives, and plant extracts, and have accumulated rich industry experience.
Established
Long-term Clients
Partner Suppliers
Annual Sales (USD)
Our pharmaceutical products consist of biological products, vaccines, western medicines, raw material, intermediates, medical consumables, with high quality and affordable prices.
Derives From The Nature To Maintain Body Health And Balance With Purity. Covering plant extracts, oils, proteins, and premium probiotics.
Cooperation on customization of Pre-Mix, Co-Crystallization and Bio-Fermentation products service to meet cutting-edge market needs.
For global enterprises, sourcing LGG involves complex logistics and quality assurance. Jiangxi Serum Pharma offers a streamlined procurement solution:
Enterprise-level procurement requires more than just a product; it requires reliability. We address the "Information Gain" by providing real-time stability data and third-party verification, ensuring that the LGG delivered today performs exactly as the sample tested six months ago.
